FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Terry Dagnon, chief operations officer for Outlook Therapeutics, discusses the latest update on ONS-5010 for the treatment of wet AMD. ONS-5010 is a formulation of bevacizumab being developed for intravitreal injection for the treatment of wet age-related macular degeneration and other retinal diseases. Currently, bevacizumab for intravitreal injection must be compounded from IV bevacizumab.